babycell®

Preserve Your Love

AN
INFINITE
BOND

supports beyond
NINE months

1800-209-0309 | babycell.in | SMS 'Babycell' to 56677

babycell®
Preserve Your Love

One life. One opportunity.

Congratulations on your pregnancy!

Your little miracle will soon make your world more beautiful and happier. As expecting parents, you must be busy preparing for your little bundle, ensuring that you give your baby nothing but the best.

Health is wealth and you now hold the key to providing a lifetime of good health for your baby by preserving the babies stem cells at the time of birth. Stem cell collection and preservation is as easy as flipping the pages of a book. As you learn more about the importance of stem cells and their preservation through this journey, we hope that you **make a responsible choice today and secure your child's and family's health for a life time.**

All about stem cells

The umbilical cord is the magical bond between the mother and the baby, whilst providing nourishment to the baby in the womb also plays a key role in protecting your family for a lifetime.

The umbilical cord is a rich source of Haematopoietic (blood forming) Stem Cells (HSC's) and Mesenchymal (tissue and organ forming) Stem Cells (MSC's). Stem cells are master cells that possess the ability to specialise and are thus used as the basic building material in the body's constant renewal process.

The HSC's are being successfully used to cure diseases like Leukaemia, Thalassemia, Sickle Cells Anaemia and more such 80+ life threatening disorders. More than 50,000 stem cell transplants have already been performed worldwide and ~ 1540 in India*. MSC's have potential to facilitate repair, regenerate and restore normal tissue function. More than 362 clinical trials using MSC's are currently in progress including treatment for Cerebral Palsy, Autism and Type 1 Diabetes**.

The umbilical cord also has ability in treating chronic diseases like hearing loss and AIDS with multiple trials in process.

The stem cells found in the cord blood and tissue are genetically unique to your baby and family. As a parent you should consider opting for cord blood stem cell preservation to protect your family from 80+ serious diseases.

*http://www.who.int/transplantation/hscx/en/

**http://bit.ly/2uuvZz9

"Since 1988, doctors have been using cord blood in lifesaving treatments. Cord blood stem cells are now being successfully used to treat conditions like Leukaemia and Thalassemia in India. The future of stem cell technology is promising and will save many lives."

Dr. Vijay Ramanan, MD, DM
Leading Clinical Haematologist specialising in Stem Cell Transplantation (Pune, India)

babycell®
Preserve Your Love

100+ treatable diseases

Cord blood stem cells can treat 90+ life threatening diseases:

Leukemia

- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
- Acute Biphenotypic Leukemia
- Acute Undifferentiated Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myelogenous Leukemia (CML)
- Juvenile Chronic Myelogenous Leukemia (JCML)
- Juvenile Myelomonocytic Leukemia (JMML)

Myelodysplastic Syndromes

- Refractory Anemia
- Refractory Anemia with Ringed Sideroblasts (Sideroblastic anemia)
- Refractory Anemia with Excess Blasts
- Refractory Anemia with Excess Blasts in Transformation
- Chronic Myelomonocytic Leukemia (CMML)

Lymphoma

- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma (Burkitt's Lymphoma)

Other Disorders of Blood Cell Proliferation

- Aplastic Anemia
- Fanconi Anemia
- Congenital Dyserythropoietic Anemia
- Paroxysmal Nocturnal Hemoglobinuria
- Sickle Cell Disease
- Beta Thalassemia Major
- Diamond-Blackfan Anemia
- Pure Red Cell Aplasia
- Amegakaryocytosis / Congenital Thrombocytopenia
- Glanzmann Thrombasthenia

Other blood complications

- Amyloidosis
- Dyskeratosis Congenita
- Myelodysplastic Syndrome

Inherited Immune System Disorders:

Severe Combined Immunodeficiency

- SCID with Adenosine Deaminase Deficiency (ADA-SCID)
- SCID which is X-linked
- SCID with absence of T & B Cells
- SCID with absence of T Cells, Normal B Cells

Omenn Syndrome

Inherited Immune System Disorders

- Infantile Genetic Agranulocytosis (Kostmann Syndrome)
- Myelokathexis
- Congenital Neutropenia
- Ataxia-Telangiectasia
- Bare Lymphocyte Syndrome
- Common Variable Immunodeficiency
- DiGeorge Syndrome
- Hemophagocytic Lymphohistiocytosis
- Leukocyte Adhesion DeficiencyLymphoproliferative Disorders
- Lymphoproliferative Disorder, X-linked
- Wiskott-Aldrich Syndrome
- Cartilage-Hair Hypoplasia
- Erythropoietic Porphyria
- Hermansky-Pudlak Syndrome
- Pearson's Syndrome
- Shwachman-Diamond Syndrome
- Systemic Mastocytosis
- Fucosidosis
- Thymic Dysplasia
- X-linked Agammaglobulinemia

Other Immune Disorders

- Evans Syndrome
- Hemophagocytosis Langerhans' Cell Histiocytosis (Histiocytosis X)
- HIV - AIDS

Myeloproliferative Disorders

- Acute Myelofibrosis
- Agnogenic Myeloid Metaplasia (Myelofibrosis)
- Polycythemia Vera
- Essential Thrombocythemia

Phagocyte Disorders

- Chediak-Higashi Syndrome
- Chronic Granulomatous Disease
- Neutrophil Actin Deficiency
- Reticular Dysgenesis

Bone Marrow Cancers

- Multiple Myeloma
- Plasma Cell Leukemia
- Waldenstrom's Macroglobulinemia

Inherited Metabolic Disorders

Mucopolysaccharidosis (MPS) Storage Diseases

- Hurler Syndrome (MPS-IH)
- Scheie Syndrome (MPS-IS)
- Hunter Syndrome (MPS-II)
- Sanfilippo Syndrome (MPS-III)
- Morquio Syndrome (MPS-IV)
- Maroteaux-Lamy Syndrome (MPS-VI)
- Sly Syndrome (MPS-VII)
- Mucolipidosis II

Leukodystrophy Disorders

- Adrenoleukodystrophy (ALD)
- Krabbe Disease
- Metachromatic Leukodystrophy
- Pelizaeus-Merzbacher Disease

Lysosomal Storage Diseases

- Niemann-Pick Disease
- Sandhoff Disease
- Wolman Disease
- Mannosidosis

Other Inherited Metabolic Disorders

- Lesch-Nyhan Syndrome
- Osteopetrosis
- Congenital Erythropoietic Porphyria (Gunther Disease)
- Gaucher Disease

Solid tumors not originating in the blood or immune system

- Neuroblastoma
- Medulloblastoma
- Retinoblastoma
- Chronic Active Epstein Barr Cancer

Others

- Hearing loss
- Hypoplastic left heart syndrome

babycell®
Preserve Your Love

Giving New Hope

Cerebral Palsy

Cerebral Palsy is the result of a brain injury or a brain malformation in the womb. It affects around 10,000 infants annually worldwide. CP affects muscles and a person's ability to control them.

Umbilical cord stem cells have shown potential in the treatment of CP. In a study, two toddlers suffering from CP underwent autologous umbilical cord blood (UCB) transfusion. Gross Motor Function Classification System (GMFCS) improvements were seen in both without any side effects thereby encouraging functional outcome improvements in children with CP.

*https://www.ncbi.nlm.nih.gov/pubmed/21335665

Type 1 Diabetes

Type 1 Diabetes, also known as juvenile diabetes, is usually diagnosed in children and young adults. In this diabetes, the body does not produce insulin.

In a study, twenty adult patients with newly diagnosed type 1 diabetes underwent MSC treatment and showed tremendous changes without any side effects. Autologous MSC transplantation in new-onset type 1 diabetes constituted a safe and promising strategy to intervene in disease progression and preserve β-cell function.



*https://www.ncbi.nlm.nih.gov/pubmed/25204974?dopt=Abstract



Congenital Heart Disease

It is also known as congenital heart anomaly which is a problem in the structure of the heart that is present at birth. Every year in India, around 78,000 infants die of Congenital Heart Disease*.

In a study conducted by S Tarui, 14 patients suffering from hypoplastic left heart syndrome (HLHS) were injected with c**ardiac progenitor cells** and no complications, including tumor formation, were reported within 36 months. This therapeutic strategy may enhance somatic growth and reduce incidence of heart failure.

*https://www.ncbi.nlm.nih.gov/pubmed/26232942?dopt=Abstract

Total Hearing Loss

Hearing loss is a common problem that often develops with age or is caused by repeated exposure to loud noises. About 63 million people in India suffer from acquired Hearing Loss.

A success story was observed where the use of umbilical cord blood stem cells has treated a child with Hearing Loss*.

Stephanie Connor acquired a virus infection during her pregnancy which had put her daughter at significant risk for brain damage and lifelong Hearing Loss at age 1.

In January 2012, Madeleine, 2, became the first child to undergo an experimental Hearing Loss treatment through stem cells from her own banked cord blood into her damaged inner ear. Madeleine has since then seen dramatic improvement in her ability to hear.



*Reference: http://abcnews.go.com/Health/Wellness/cord-blood-stem-cells-restore-hearing-toddler/story?id=16750718

The above case studies offer a compelling reason why parents should consider preserving their child's cord blood, since it may offer a treatment option in the future

Hospitals that have reported heamatopoitic stem cell transplants

- Christian Medical College (CMC), Vellore
- Tata Medical Center, Kolkata
- Apollo Specialty Hospital, Chennai
- Narayana Health, Bangalore
- Medanta-The Medicity, New Delhi
- BL Kapoor, New Delhi
- Deenanath Mangeshkar Hospital, Pune
- BGS Global – Bangalore
- GCRI – Ahmedabad
- Rajiv Gandhi Cancer Institute, Delhi
- Apollo Hospital, Ahmedabad
- AIMS, Kochi
- Sahyadri Superspeciality Hospital
- Manipal Hospitals, Bangalore
- Sterling Hospital, Ahmedabad
- ARTEMIS Hospital, Gurgaon
- MIOT Hospital, Chennai
- Apollo Hospital, Delhi
- Meenakshi Mission Hospital & Research Center
- Apollo Glen Eagles Hospital, kolkata
- Basavatarakam Indo American Cancer Hospital, Hyderabad
- Cancer Institute, Adyar
- Christian Medical College (CMC), Ludhiana
- HCG, Bangalore
- PD Hinduja Hospital, Mumbai
- SRMC, Chennai
- Tata Medical Center, Mumbai

Reference:
http://datri.org/transplant-centers/

About us

Regenerative Medical Services Pvt. Ltd (RMS) started its journey in 2009, when the concept of umbilical cord blood banking in India was just another science experiment; the outcome of which was unknown to most.

Babycell™, established in 2009, is India's premium Cord Blood Bank. We understand your baby means everything to you, hence we strive to preserve your love in the safest and purest environment possible. We are leaders not only in umbilical cord blood preservation but our value-added services expand in providing Diagnosis, best Processing Technology and customized Therapeutic Solutions for you and your loved ones.

Driven with passion and powered with cutting edge technology, Babycell™ has become one of the preferred partners for stem call banking in India. Babycell™ has gained the trust of more than 20,000 thousand families in a short span of time and is growing family by family.



babycell®
Preserve Your Love

Milestones

2009

Founded in 2009 as the first Indian biotechnology company to introduce cutting edge technology platform for regenerative medicine in India

2010

- Achieved ISO in the very first year of operations
- Appointed Deloitte India, the global leaders in auditing as our financial auditors from the year 2010 till date
- Introduced New Born Screening

2011

- Certified with GMP, GLP and GCP in its 2nd year of operations
- Selected as one of the top five Leaders of Tomorrow by ET Now

2012

- Satyen Sanghavi, CSO featured as the Young Entrepreneur on CNBC Young Turks
- Selected as one of the top five Leaders of Tomorrow by ET Now again!
- Introduced Sickle Cell Screening

2013

- Presented at Stem Cells Asia Regenerative Medicine Congress, Singapore
- Received the Healthcare Excellence Award For Cord Blood Bank by Worldwide Achievers and Headlines Today
- Introduced Mummy & Tummy events for pregnant ladies

2014

- Product Innovation Award by Asian Confederation of Businesses & stars of the Industry
- Invited for Bio-Africa conference, Mauritius to speak about RMS's advanced regenerative medical therapies
- Satyen Sanghavi, CSO featured on CNBC Africa's Power Lunch, giving an update on stem cell technology

2015

- Launch of Sibling Program as CSR for children requiring stem cell transplant.
- SKOCH order of merit awarded for India's Best SME's (2015)
- Invited to Global Business Summit
- Initiated contribution of a portion of the sales proceeds towards Cancer patients treatment

2016

- 1st Cord blood transplantation approval for a Patient diagnosed with Mucopolysaccharidosis Type VI (MPS VI) carried out by Dr. Revathy Raj (Apollo Speciality Hospital, Chennai).
- Cord Blood transplatation was performed for baby suffering from -Thalassemia Major, carried out by Dr. Vijay Ramanan (Ruby Hall Clinic, Pune).
- RMS Laboratory received inhouse R&D unit recognition from Department of Scientific and Industrial Research(DSIR)
- RMS received Market Authorization for Chondron and Ossron along with filing of patent for Chondron, Ossron and Uregrow

2017

- RMS got DCGI approval to market cell therapy drug - Ossron and Chondron
- Exclusively associated with Apollo Hospitals to provide Regrow services across India.

Accreditation



This is to certify that:

Regenerative Medical Services Pvt. Ltd.
Plot No. 22, Shah Industrial Estate
Nangargaon
Lonavla, Taluka: Maval
Pune 410 401
Maharashtra
India

Holds Certificate No: **606524**
is complying with the requirements of ***Good Manufacturing Practices (GMP)*** *for the following scope:*

1. **The Collection, Processing, Testing, Banking and Release of Human Umbilical Cord Blood and Cord Tissue Units;**
2. **The Collection, Processing, Testing and Release for Implantation of Chondron; and**
3. **The Collection, Processing, Testing and Release for Implantation of Ossron.**

For and on behalf of BSI:

Managing Director, BSI India, Venkataram Arabolu

Originally Registered Date: **12/12/2016** Effective Date: **12/12/2016**

Latest Revision Date: **12/12/2016** Expiry Date: **11/12/2017**

Page: **1 of 1**

..making excellence a habit."

This certificate remains the property of BSI India and shall be returned immediately upon request.
To check it's validity telephone: +91 11 2692 9000
Further clarifications regarding the scope of this certificate and the applicability of GMP requirements may be obtained by consulting the organization.

BSI Group India Private Limited
The Mira Corporate Suites (A-2), Plot 1&2, Ishwar Nagar, New Delhi 110 065, India
BSI Management Systems India Private Limited is a subsidiary of British Standards Institution.

GMP (Good Manufacturing Practices) 2016-17



This is to certify that:

Regenerative Medical Services Pvt. Ltd.
Plot No. 22, Shah Industrial Estate
Nangargaon
Lonavla, Taluka: Maval
Pune 410 401
Maharashtra
India

Holds Certificate No: **606699**
is complying with the requirements of ***Good Clinical Practices (GCP)*** *for the following scope:*

1. **The Collection, Processing, Testing, Banking and Release of Human Umbilical Cord Blood and Cord Tissue Units;**
2. **The Collection, Processing, Testing and Release for Implantation of Chondron; and**
3. **The Collection, Processing, Testing and Release for Implantation of Ossron.**

For and on behalf of BSI:

Managing Director, BSI India, Venkataram Arabolu

Originally Registered Date: **12/12/2016** Effective Date: **12/12/2016**

Latest Revision Date: **12/12/2016** Expiry Date: **11/12/2017**

Page: **1 of 1**

..making excellence a habit."

This certificate remains the property of BSI India and shall be returned immediately upon request.
To check it's validity telephone: +91 11 2692 9000
Further clarifications regarding the scope of this certificate and the applicability of GCP requirements may be obtained by consulting the organization.

BSI Group India Private Limited
The Mira Corporate Suites (A-2), Plot 1&2, Ishwar Nagar, New Delhi 110 065, India
BSI Management Systems India Private Limited is a subsidiary of British Standards Institution.

GCP (Good Clinical Practices) 2016-17



This is to certify that:

Regenerative Medical Services Pvt. Ltd.
Plot No. 22, Shah Industrial Estate
Nangargaon
Lonavla, Taluka: Maval
Pune 410 401
Maharashtra
India

Holds Certificate No: **606698**
is complying with the requirements of ***Good Laboratory Practices (GLP)*** *for the following scope:*

1. **The Collection, Processing, Testing, Banking and Release of Human Umbilical Cord Blood and Cord Tissue Units;**
2. **The Collection, Processing, Testing and Release for Implantation of Chondron; and**
3. **The Collection, Processing, Testing and Release for Implantation of Ossron.**

For and on behalf of BSI:

Managing Director, BSI India, Venkataram Arabolu

Originally Registered Date: **12/12/2016** Effective Date: **12/12/2016**

Latest Revision Date: **12/12/2016** Expiry Date: **11/12/2017**

Page: **1 of 1**

..making excellence a habit."

This certificate remains the property of BSI India and shall be returned immediately upon request.
To check it's validity telephone: +91 11 2692 9000
Further clarifications regarding the scope of this certificate and the applicability of GLP requirements may be obtained by consulting the organization.

BSI Group India Private Limited
The Mira Corporate Suites (A-2), Plot 1&2, Ishwar Nagar, New Delhi 110 065, India
BSI Management Systems India Private Limited is a subsidiary of British Standards Institution.

GLP (Good Laboratory Practices) 2016-17

DSIR FDA GMP ISO 13485 GCP GLP

babycell®
Preserve Your Love

Accreditation

bsi.

By Royal Charter

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2003

This is to certify that:

Regenerative Medical Services Pvt. Ltd.
2-ABC, ACME, 2nd Floor
Above Indusind Bank
Andheri-Kurla Road, Andheri (E)
Mumbai 400 059
Maharashtra
India

Holds Certificate No: **MD 559280**

and operates a Quality Management System which complies with the requirements of ISO 13485:2003 for the following scope:

1. The collection, processing, testing, banking and release of umbilical cord blood and cord tissue units;
2. The collection, processing, testing and release for implantation of Chondron; and
3. The collection, processing, testing and release for implantation of Osteon.

For and on behalf of BSI:

Frank Lee, EMEA Compliance & Risk Director

Original Registration Date: 04/05/2010
Latest Revision Date: 15/03/2016

Effective Date: 04/05/2016
Expiry Date: 18/03/2019

Page: 1 of 2

...making excellence a habit.

This certificate was issued electronically and remains the property of BSI and is bound by the conditions of contract.
An electronic certificate can be authenticated online.
Printed copies can be validated at www.bsi-global.com/ClientDirectory or telephone +91 11 2692 9000.
Further clarifications regarding the scope of this certificate and the applicability of ISO 13485:2003 requirements may be obtained by consulting the organization.
This certificate is valid only if provided original copies are in complete set.

Information and Contact: BSI, Kitemark Court, Davy Avenue, Knowlhill, Milton Keynes MK5 8PP. Tel: + 44 845 080 9000
BSI Assurance UK Limited, registered in England under number 7805321 at 389 Chiswick High Road, London W4 4AL, UK.
A Member of the BSI Group of Companies.

ISO 13485:2003
This is specifically for medical manufacturing
2016-17

सूचना का अधिकार

TELEGRAM : SCINDRECH
दूरभाष/TEL : 26962819, 26567373
(EPBAX) : 26565694, 26562133
: 26565687, 26562144
: 26562134, 26562122
फैक्स/FAX : 26960629, 26529745
Website : http://www.dsir.gov.in

भारत सरकार
विज्ञान और प्रौद्योगिकी मंत्रालय
वैज्ञानिक और औद्योगिक अनुसंधान विभाग
टेक्नोलॉजी भवन, नया महरौली मार्ग,
नई दिल्ली – 110 016

GOVERNMENT OF INDIA
MINISTRY OF SCIENCE AND TECHNOLOGY
Department of Scientific and Industrial Research
Technology Bhavan, New Mehrauli Road,
New Delhi - 110 016

No. TU/IV-RD/3999/2016

Dated: 14 July, 2016

To

M/S Regenerative Medical Services Pvt. Ltd.
2-ABC, Acme Plaza, Second Floor
Andheri-Kurla Road, Andheri (E)
Mumbai – 400 059
Maharashtra

Subject: RECOGNITION OF YOUR IN-HOUSE R&D UNIT(s)

Dear Sirs,

This has reference to your application for recognition of your In-House R&D unit(s) by the Department of Scientific and Industrial Research.

2. This is to inform you that it has been decided to accord recognition to the In-House R&D unit(s) of your firm at **22, Shah Industrial Estate,Nagargaon, Lonavala, Pune, Maharashtra** from **29.06.2016** to **31.03.2018.**Terms and conditions pertaining to this recognition are given overleaf.

3. Kindly acknowledge the receipt of this letter.

UNCONTROLLED COPY
REGENERATIVE MEDICAL SERVICES
PVT. LTD.

Yours faithfully,

(Dr. S. K. Deshpande)
Scientist - 'G'

Recognition of R & D unit by DSIR
2016-17

Awards

The top 5 Leaders of Tomorrow by ET Now for 2 consecutive years: 2011and 2012

Healthcare Excellence Award for Cord Blood Bank by Worldwide Achievers (2013)

Product Innovation Award by Asian Confederation of Businesses and Stars of the industry (2014)

India's Best SME's (2015) by Skotch Order of Merit.

Recognitions

5th annual

Stem Cells Asia
Regenerative Medicine Congress
2013

Speaker and Presenter at Stem Cells Asia Regenerative Medical Congress, Singapore

Speaker at Bio Africa Conference, Mauritius

Featured in CNBC Young Turks

Selected as Top 5 Leaders of Tomorrow by ET Now

babycell®
Preserve Your Love

Cell Processing Centre™


Cryogenic Storage Tanks


Processing Floor


Final Cryopreservation


Processing


Colony Forming Unit Assay

Cell Processing Centre™


Cell Extratction


Cell Counter


Cell Culturing


Control Rate Freezing


CPC Team


Centrifugation


Barcode Scanning

babycell®
Preserve Your Love

Why Babycell™

5 STAR TREATMENT

- Regrow Health Cover
- BIO CORD®
- BIO CORD® Superpower
- Critical Congenital Heart Defects
- Sibling Program

PEACE OF MIND

- CFU Assay
- HLA typing
- Haemoglobinopathy Test
- New Born Screening
- Data logger

babycell®
Preserve Your Love

Saving Cord Blood is easier than you think



Meet
Our key account manager will explain various benefits and guide you through the enrolment process

Receive
Upon registration, Babycell™ collection kit will be sent to you

Collect
Call 1800-209-0309 on your way to the hospital. Bring your kit along for sample collection

Transport
Logistics team will safely transfer the sample to Babycell™ Cell Processing Centre

Preserve
With the Certificate of Cryopreservation you can rest assured your baby's health is preserved for life

Retrieve
Transport specialists will access the medical condition and prescribe suitable transplantation procedure

Cryopreservation Report

Certificate of Cryopreservation

Client ID :	Lab ID :
Mother's Name (Client) :	Father's Name :
Date Of Collection :	Date Of Report :
Date Of Processing :	

Product: Cord Blood	
Nature Of Packing and Content	**25 ml Of Cord Blood Unit Containing Hematopoietic Progenitor Cells (20 ml proccessed CB With 5 ml cryoportectant) Stored in Freezing bag covered with overwrap bag**
Storage Condition	**Product stored in Vapour phase of Liquid Nitrogen**

Sr No.	Test	Specification	Results
1	Blood Group	Blood Group (ABO) And Rh Factor	
2	Total Nucleated Cell Count *Automated Cell Counter*	NLT 50 X 10 • / unit	
3	Total Mononucleated Cell Count *Automated Cell Counter*	Observed Value / unit	
4	Total CD 34+ Stem Cell Count *By Flow Cytometry*	NLT 1.3 X 10 • / unit	
5	TNCC Cell Viabillity (%) *By Flow Cytometry*	NLT 70%	
6	CD34+ Cell Viability (%) *By Flow Cytometry*	NLT 70%	
7	Hematocrit (%)	Observed Value (%)	
8	Sterility Testing* *By Direct Inocultaion Method Automated Microbial Detection System*	Negative	

Remarks :-

Cord Blood Processed and Cryopreserved Successfully

NLT : Not Less Than
* If sterility is positive,please refer microbial identification and AST report.

Medical Director

Ref SOP/QA/GEN/023

Lab Address : Regenarative Medical Services Pvt.Ltd.22, Shah Industrial Estate,Nagargaon, Lonavala - 410401, Tal:Maval, Dist: Pune,M.S.India. Tel : (+91) 02114-273741-42-43.

Cryopreservation Report

Certificate of Cryopreservation

Client ID :	Lab ID :
Mother's Name (Client) :	Father's Name :

Product : Maternal Blood

Sr.No	Test	Specification	Results
1	HIV I & II Antibodies	Negative	
2	HBs Ag (Surface Antigen)	Non-reactive / Reactive	
3	HBc Antibodies	Non-reactive / Reactive	
4	HCV Antibodies	Non-reactive / Reactive	
5	HTLV I & II Antibodies	Negative / Positive	
6	CMV IgM	Negative / Positive	
7	CMV IgG	Immune / Non-Immnue	
8	Malarial Parasite	Not Detected / Detected	
9	Syphilis Antibodies	Non-reactive / Reactive	

Remarks :-

Medical Director
Dr.Yogesh Gavandi
(M.B.B.S.,M.D.(Pathology))
Ref SOP/QA/GEN/023

1. Cryopreservation report Disclaimer & Confidentiality

Disclaimer: The Laboratory of Regenerative Medical Services Private Limited (RMS Lab) is certified annually to ISO 13485 standards, and regularly inspected by the FDA. Whilst every effort has been made to ensure the accuracy of the information contained in this report, all investigations are carried out with the highest professional standard of due care and skills, based on the scientific knowledge by our medical experts but limited to sensitivity and specificity of individual assay as well as the Umbilical Cord Blood received by the Laboratory. Regenerative Medical Services Pvt. Ltd, its officers, directors, agents, attorneys, employees, shareholders, and affiliates do not take any responsibility or liability for any errors that may happen in the pre-analytic, analytic and post-analytic phase of testing due to failure of the systems, process and procedure which is beyond the control of RMS Lab involved in the transmission and reporting of the test result. Isolated laboratory investigation does not confirm final diagnosis.

Confidentiality: This is a confidential report from Regenerative Medical Services Pvt. Ltd. The contents of this report and any attachments are solely intended for the addressee(s) and in all likelihood, contains information that is legally privileged. If you are not the intended recipient of this report, we request you to kindly return the copy immediately. Please also simultaneously disregard the contents herein and destroy any copies, if any created.

Lab Address : Regenarative Medical Services Pvt.Ltd.22, Shah Industrial Estate,Nagargaon, Lonavala - 410401,
Tal:Maval, Dist: Pune,M.S.India. Tel : (+91) 02114-273741-42-43.

Cryopreservation Report

CFU Report

Client ID :	Lab ID :
Mother's Name (Client) :	Father's Name :

Hematopoietic Colony Forming Units Assay (CFU Assay)

Product: Cord Blood

Sr No.	Test	Specification	Results ***
01	BFU-E*	Growth (for positive results of Potency)	
02	CFU-GM**	Growth (for positive results of Potency)	



BFU-E



CFU-GM

Importance of CFU : This test is an indication of the proliferative capacity of the stem cell, which reflects upon the regenarative capacity of the Cryopreserved hematopoietic stem cells.

Remarks :-

* BFU-E : Burst Forming Unit-Erythrocyte
** CFU-GM : Colony Forming Unit-Granulocyte Macrophage
*** Value is representative of total hematopoietic progenitor colonies in 25 ml cryopreserved cord blood

Date : 12.06.2017

Medical Director

Ref SOP/QA/GEN/023

1. Cryopreservation report Disclaimer & Confidentiality

Disclaimer: The Laboratory of Regenerative Medical Services Private Limited (RMS Lab) is certified annually to ISO 13485 standards, and regularly inspected by the FDA. Whilst every effort has been made to ensure the accuracy of the information contained in this report, all investigations are carried out with the highest professional standard of due care and skills, based on the scientific knowledge by our medical experts but limited to sensitivity and specificity of individual assay as well as the Umbilical Cord Blood received by the Laboratory. Regenerative Medical Services Pvt. Ltd, its officers, directors, agents, attorneys, employees, shareholders, and affiliates do not take any responsibility or liability for any errors that may happen in the pre-analytic, analytic and post-analytic phase of testing due to failure of the systems, process and procedure which is beyond the control of RMS Lab involved in the transmission and reporting of the test result. Isolated laboratory investigation does not confirm final diagnosis.

Confidentiality: This is a confidential report from Regenerative Medical Services Pvt. Ltd. The contents of this report and any attachments are solely intended for the addressee(s) and in all likelihood, contains information that is legally privileged. If you are not the intended recipient of this report, we request you to kindly return the copy immediately. Please also simultaneously disregard the contents herein and destroy any copies, if any created.

Lab Address : Regenarative Medical Services Pvt.Ltd.22, Shah Industrial Estate,Nagargaon, Lonavala - 410401, Tal:Maval, Dist: Pune,M.S.India. Tel : (+91) 02114-273741-42-43.

HLA Typing Certificate

Testing partner : Histogenetics

HISTOGENETICS

300 Executive Blvd, Ossining, New York - 10562.
Phone : 914-762-0300. Fax : 914-762-4441. Website : www.histogenetics.com
ASHI # 03-1-NY-26-2. CLIA # 33D0985173
Soo Young Yang Ph.D / Nezih Cereb M.D., Directors
Email : customerservice@histogenetics.com

HLA TYPING REPORT

Sample Information

First Name :
Last Name :
Client ID :
Collected On :
Sample ID :
Received On :

A*	B*	C*	DRB1*	DRB345*	DQB1*	DQA1*	DPB1*	DPA1*
02:11:01G	40:06:01G	NA	14:04:01	NA	NA	NA	NA	NA
24:02:01G	40:01:01G	NA	15:02:01G	NA	NA	NA	NA	NA

Typing Status : Complete

Null Allele Resolution Status :

Note:

1. **Allele Database Version : 3.25.0 (Jul 2016)**
2. **Allele bearing suffix G : The first allele of the Included Alleles. Included alleles in the appendix**
3. **Sequencing Technology: Illumina Miseq**
4. **Reagent Information : Lot Number available upon request.**

Report History

Reported Date	History	Comments
29-Jun-2017		

DIRECTOR / ASSOCIATE DIRECTOR _____

HLA Typing Certificate

HISTOGENETICS
300 Executive Blvd, Ossining, New York - 10562.
Phone : 914-762-0300. Fax : 914-762-4441. Website : www.histogenetics.com
ASHI # 03-1-NY-26-2. CLIA # 33D0985173
Soo Young Yang Ph.D / Nezih Cereb M.D., Directors
Email : customerservice@histogenetics.com

HLA TYPING REPORT - APPENDIX

Locus	G Code	NMDP Allele Code	Exon Sequenced	Included Alleles
Sample ID :				
A	02:11:01G	02:AZGG	Exon 2,3	02:11:01/02:69
A	24:02:01G	24:ABGEW	Exon 2,3	24:02:01:01/24:02:01:02L/24:02:01:03/24:02:01:04/24:02:01:05/ 24:02:01:06/24:02:01:07/24:02:01:08/24:02:03Q/24:02:10/ 24:02:13/24:02:31/24:02:40/24:02:43/24:02:44/24:02:56/ 24:02:65/24:02:79/24:02:80/24:02:81/24:02:82/24:02:83/ 24:02:84/24:09N/24:11N/24:40N/24:76/24:79/24:83N/24:144/ 24:150/24:153/24:154/24:155N/24:163N/24:183N/24:231/24:249/ 24:250/24:251/24:263/24:264/24:265/24:266/24:267/24:268/ 24:269/24:270/24:271
B	40:01:01G	40:ANAGY	Exon 2,3	40:01:01/40:01:02/40:01:25/40:01:36/40:01:37/40:01:42/40:01:45/ 40:55/40:141/40:150/40:151/40:179/40:221/40:236/40:241/40:247/ 40:264/40:272/40:278/40:299/40:301/40:329/40:338N
B	40:06:01G	40:06	Exon 2,3	40:06:01:01/40:06:01:02/40:06:03/40:06:04/40:06:08
DRB1	14:04:01		Exon 2	
DRB1	15:02:01G	15:02:01	Exon 2	15:02:01:01/15:02:01:02

Histogenetics lab is certified by
ASHI - American Society for Histocompatibility & Immunogenetics
CLIA - Clinical Laboratory Improvement Amendments

Heamoglobinopathy Report

Testing partner : Metropolis

BTXXXXX
Tel No. : XXXXXXXXXX
PID NO: XXXXXXXXXXX
Age: XX Year(s) Sex: NA

Reference:
Sample Collected At:

VID:XXXXXXXXXXX Collected On:
Registered On:
XX/XX/XXXX XX:XX AM
Collected On:
XX/XX/XXXX XX:XX AM
Reported On:
XX/XX/XXXX XX:XX PM

Abnormal Haemoglobin StudiesHb VariantsBlood

(XXX Whole Blood)

Investigation	Observed Value	Unit
Foetal Haemoglobin (HbF)	XX	%
Haemoglobin A0 (Hb A0)	XX	%
Haemoglobin A2 (HbA2)	XX	%
Impression	.....	
	History provided : - Cord blood sample. Kindly correlate with age of the patient.	
Comment	-	
Suggestion	-	
Method	HPLC	

Interpretations & Remarks:-

1. All results have to be correlated with age and history of blood transfusion If there is history of blood transfusion in last 3 months, repeat testing after 3 months from last date of transfusion is recommended.
2. In case of haemoglobinopathy, parents or family studies and counseling is advised.
3. This test detects Beta thalassaemia and haemoglobinopathies. DNA analysis is recommended to rule out alpha thalassaemia and silent carriers.
4. Linearity range of HbF is 1-40%, however, values in excess of the reportable range have been provided for ease of interpretation.
5. Mild to moderate increase in fetal heamoglobin can be seen in some acquired conditions like Pregnancy, Megaloblastic anaemia, Thyrotoxicosis, Hypoxia, Chronic kidney disease, Recovering marrow, MDS, Aplastic anaemia, PNH, Medications (Hydroxyurea, Erythropoietin) etc.
6. P3 window- Above 10% is often indicative of either denatured forms of hemoglobins or may suggest a possibility of abnormal haemoglobin variant. Hence,repeat analysis with fresh sample or DNA studies is advised.
7. P2 window- Above 10% is indicative of either glycated haemoglobin requiring correlation with diabetic status or may suggest a possibility of abnormal haemoglobin variant requiring further DNA studies for confirmation.

Heamoglobinopathy Report

BTXXXXX

Tel No : XXXXXXXXXX
PID NO: XXXXXXXXXX
Age: XX Year(s) Sex: NA

Reference:
Sample Collected At:

VID: 11150959830
Registered On:
XX/XX/XXXX XX:XX AM
Collected On:
XX/XX/XXXX XX:XX AM
Reported On:
XX/XX/XXXX XX:XX PM

Bio-Rad Variant-II, Serial # 12853

PATIENT REPORT
V2_BThal

Patient Data		Analysis Data	
Sample ID:	112058402	Analysis Performed:	XX/XX/XXXX XX:XX:XX
Patient ID:	11150959830	Injection Number:	732
Name:	BTXXXXX	Run Number:	60
Physician:		Rack ID:	
Sex:		Tube Number:	3
DOB:		Report Generated:	XX/XX/XXXX XX:XX:XX
Comments:		Operator ID:	

Peak Name	Calibrated Area %	Area %	Retention Time (min)	Peak Area
Unknown	---	0.1	0.61	1299
F	80.1*	---	1.18	870365
P3	---	1.1	1.73	12793
Ao	---	21.8	2.54	245849

Total Area: 1,130,307

F Concentration = 80.1* %
A2 Concentration = %

*Values outside of expected ranges

Analysis comments:



-- End of Report --

Page 3 of 3 Dr. XX MD(Path)

Metropolis lab is certified by
NABL - National Accreditation Board for Testing & Calibration Laborities
CAP - College of American Pathologists

babycell®
Preserve Your Love

New Born Screening

Testing partner :
Nextline Diagnostics (Bharat serum)

NBS list from dried blood specimen

A. Inborn Errors of Amino Acid Metabolism

1 Phenylketonuria (PKU)
2 Benign hyperphenylalaninemia
3 Defects of biopterin cofactor biosynthesis
4 Defects of biopterin cofactor regeneration
5 Maple syrup urine disease
6 Classical citrullinemia
7 Citrullinemia type-2 (citrin deficiency)
8 Arginosuccinate synthase (ASS) deficiency
9 Arginosuccinic aciduria
10 Hyperornithinemia, Hyperammoninemia Hyperhomocitrullinemia (HHH) syndrome
11 Arginase deficiency/Argininemia
12 Neonatal Tyrosinemia
13 Tyrosinemia I
14 Tyrosinemia type II
15 Tyrosinemia III
16 Homocystinuria
17 Hypermethioninemia

B. Inborn Errors of Fatty Acid Metabolism

18 Carnitine transporter deficiency (Carnitine uptakedeficiency)
19 Carnitine/acylcarnitine Translocase deficiency
20 Carnitine palmityl transferase deficiency type I
21 Carnitine palmityl transferase deficiency type II
22 Short chain acyl co A dehydrogenase deficiency
23 Short chain hydroxy acyl co A dehydrogenase deficiency
24 Medium chain acyl CoA dehydrogenase deficiency
25 Medium chain ketoacyl coA thiolase deficiency
26 Very long chain acyl-CoA dehydrogenase deficiency
27 Long chain L-3-hydroxy acyl-CoA dehydrogenase deficiency
28 Trifunctional protein deficiency
29 Multiple acyl-CoA dehydrogenase deficiency/Glutaric acidemia type II
30 Medium chain L-3 hydroxy acyl coA dehydrogenase deficiency

C. Inborn Errors of Organic Acid Metabolism

31 Glutaric acidemia type I
32 Isovaleric acidemia
33 2-Methylbutyryl-CoA-dehydrogenase deficiency
34 Propionic acidemia
35 Methylmalonyl-CoA mutase deficiency
36 Methylmalonic acidemia
37 Methylmalonic acidemia (mutase)
38 3-Methylcrotonyl-CoA carboxylase deficiency
39 Malonic aciduria
40 3-Hydroxy 3-methyl glutaric acidemia
41 β-Ketothiolase deficiency
42 Multiple CoA carboxylase deficiency
43 Isobutaryl CoA dehydrogenase deficiency
44 Malonyl-CoA decarboxylase deficiency
45 Holocarboxylase deficiency
46 3- Methyl glutaconyl Co A hydratase deficiency

D. Biochemical DELFIA TRF

47 Congenital Hypothyroidism
48 Congenital Adrenal Hyperplasia
49 Galactosemia
50 Glucose-6-Phosphate Dehydrogenase Deficiency
51 Cystic Fibrosis
52 Biotinidase Deficiency

Biological reference intervals

Analyte	(µM)
C0-carnitine	12 - 100
C2-carnitine	< 72
C3-carnitine	< 6.34
C4-carnitine	< 1.07
C5-carnitine	< 0.48
C5DC-carnitine	< 0.56
C6-carnitine	< 0.17
C8-carnitine	< 0.24
C10-carnitine	< 0.35
C12-carnitine	< 0.41
C14-carnitine	< 0.50
C16-carnitine	< 9.89
C18-carnitine	< 2.06

Analyte	(µM)
Alanine	< 736
Arginine	< 55
Aspartic acid	< 420
Citrulline	< 50
Glutamic acid	< 1073
Glycine	< 1001
Leucine/Isoleucine	< 300
Methionine	< 44
Ornithine	< 453
Phenyalanine	<120
Tyrosine	< 248
Valine	< 212

Mummy & Tummy Program

Babycell proudly presents **'Mummy Ki Paathshaala'**, where all the lovely to be mommies get a chance to experience going back to school and learning about motherhood!
Mummy ki Paathsaala is an interactive series of sessions to highlight information about pregnancy diet, pregnancy yoga and exercises, labor and delivery tips
'Mummy Ki Paathshaala' not only helps answer your questions about child delivery and antenatal care, but also helps you find your way to being an awesome parent!
MKP covers some important aspects of pregnancy like the following:

Client Benefit Program

babycell®
Preserve Your Love

Regrow Therapies

CHONDRON®
Cartilage Cell Therapy

India's first FDA approved permanent, easy and natural Cartilage cell therapy

BENEFITS

- Targeted, personalized Cell Therapy
- Regeneration of hyaline like cartilage
- Minimally invasive procedure
- Further progression of osteoarthritis is ceased
- Complete restoration of range of motion
- Active normal life involving sports

DON'T REPLACE, REGROW.

Regrow your Cells. Rebuild your Life®.

DSIR FDA GMP ISO 13485 GCP GLP

Case Studies

1 Indication : Grade IV Osteochondritis Dissecans Lateral Femoral Condyle Left Knee



Pre-OP MRI



Post-OP MRI

2 Indication : Grade IV Osteochondral defect Medial Femoral Condyle Right Knee



Pre-OP MRI



Post-OP MRI

3 Indication : Grade IV Osteochondral defect Medial Femoral Condyle Left Knee



Pre-OP MRI



Post-OP MRI

babycell®
Preserve Your Love

Regrow Therapies

OSSRON™
Bone Cell Therapy

World's first FDA approved permanent, easy and natural bone cell therapy

BENEFITS

- Targeted, personalized Cell Therapy
- Accelerated bone healing
- Three-dimensional bone regeneration
- Complete relief from pain
- New blood supply is initiated which further supports bone growth
- Active normal life

DON'T REPLACE, REGROW.

Regrow your Cells. Rebuild your Life®.

DSIR FDA GMP ISO 13485 GCP GLP

Case Studies

1 Indication : Left unilateral AVN Grade: II



Pre-OP MRI



Post-OP MRI

2 Indication : Right Unilateral AVN Grade: II



Pre-OP MRI



Post-OP MRI

3 Indication : Left Unilateral AVN Grade: II



Pre-OP MRI



Post-OP MRI

Spreading Smiles

Cord blood Stem cells saved Prerna from Dreadful Diseases MPS6

At the age of 2, Prerna's parents sensed something wrong with her structural formation and hence took doctors' opinions. Post a thorough check from specialist of Hinduja hospital, Mumbai. Prerna was diagnosed with Mucopolysaccharidosis Type VI popularly known as MPS 6. It is caused by deficiency of the enzyme N-acetyl- galactosamine-4-sulphatase. The symptoms for this disease are weak bone, bone cartilage disorders, enlargement of liver and spleen. On doctor's suggestion, Prerna's parents went for another child and stored their second child's umbilical cord blood for Prerna's treatment of Mucopolysaccharidosis Type VI metabolic condition (MPS-VI). Prerna's parents approached Babycell under sibling program. On 19th January 2016, the transplant took place at Apollo Specialty Hospital, Chennai by Dr. Revathi Raj. The transplant was successful and Prerna has since then has shown tremendous improvements and after 1 year of follow up, we learnt that Prerna is recovering well.

Disclaimer: Names of the patient have been changed to protect the identity of the patient and family.



Cord blood Stem cells saved Veena from Thalassemia Major

Veena was born with B- Thalassemia Major. Thalassemia major occurs when a child inherits two mutated genes one from each parent. The symptoms of these disease are fatigue, weakness, jaundice, swollen abdomen, dark urine and deformities of the facial bones. Veena's parents did not store her cord blood at birth. Since Veena had no permanent cure for her Thalassemia Transplant, Physician Dr. Vijay Ramanan suggested Veena's parents to have another baby so that they can use their second child's cord blood stem cells to cure Veena from Thalassemia. Veena's parents approached Babycell for her treatment under their sibling program. On 29th July 2016, the transplant took place at Ruby Hall Clinic, Pune. The transplant went well and after 6 months of follow-up, Veena is seen recovering well. Moreover, there are no signs and symptoms of the disease. Today, the family is relieved as they had, once, lost hopes of her recovery.

Disclaimer: Names of the patient have been changed to protect the identity of the patient and family.

babycell®
Preserve Your Love

Press Releases

Business Line

The Hindu • Business Line
Thursday, July 21, 2011

Babycell reports spurt in demand to store umbilical cords

Madhumathi D.S.
Bangalore, July 19

As if monsoon discounts and off-season FMCG showers are not enough, a stem cell bank has packaged one such plan for babies that will be born on August 15.

Regenerative Medical Services Ltd, a fully owned subsidiary of the Mumbai-based active pharma ingredients manufacturer Satyan Pharmaceuticals P Ltd, said it had seen 25 per cent rise in parents enrolling to store their due-in-August babies' umbilical cord blood cells after it offered earlier this month an 85 per cent cut for Independence Day births.

The average monthly strike rate for RMS's cord blood stem cell banking arm Babycell was 275 enrolments, according to Mr Satyen Sanghavi, Chief Scientist of the family-owned RMS.

Pan-India, "cord blood stem cell banking has an annual growth rate of 230 per cent. Since we started operating in 2009, 2500 people have enrolled with us," said Mr Sanghavi.

Among Babycell's customers are a vegetable vendor from Vashi, TV artistes, celebrities and companies.

The demand among parents to store their unborn child's umbilical cord cells at birth was only going up, he said, even as the draft guidelines on stem cell research and banking await approval. Started in November 2009, Babycell generates 60 per cent of RMS's turnover — which includes another regenerative stream, that of therapies using adult stem cells.

It was partly this growth of the cord blood stem cell banking that was driving Babycell to new cities and towns. "We are now focussing on the South and East. Although there are three major companies in the South we expect to do 35 per cent of sales from the South by 2012," Mr Sanghavi said.

Apart from Fortis and boutique child-birth clinic Cradle in Bangalore, Babycell is in talks to tie up with top hospitals for connecting with parents-to-be; and with diagnostic labs which would be collection franchisees in Coimbatore, Kochi, Hyderabad, Patna, Nagpur and Nashik. The samples are screened and stored at the Rs 25-crore Lonavla lab.

Through its technology tie-up with South Korea's Sewon Cellontech, RMS provides cellular therapies that re-grow tissues from adult cells. Mr Sanghavi said hospitals used them to treat burns, wounds, knee joint problems, pain, cosmetic and gynaecological procedures. "There is a huge potential for stem cell therapies that can treat 75 diseases from leukaemia, thalassemia to diabetes and brain injury. It is wrong to say there are too many cord blood banks. In fact, by 2015, there would be 15 registered companies compared to the present seven or eight," Mr Sanghavi added.

M&Bevents

M&B Event!

ROCKING TIME!

Babycell, one of India's leading stem cell banks, organised a holistic pregnancy care carnival for mums between 11am and 4.30 pm on September 1 at Bengaluru's MLR Convention Centre in JP Nagar, in partnership with brands Pigeon and Palmers. Mother & Baby magazine was media partner for this exciting event. Their Mother Care Forum had a series of informative sessions from eminent birthing experts from the industry and a lot of interactive workshops like bellydancing and fun games. TV soap actors Anup Soni and Smita Bansal (from the popular show Balika Vadhu), were happy to share their experience with Babycell and their reasons for banking their babies' stem cells. Sports nutritionist Dr Gayatri Thakur gave diet and nutrition tips for mums-to-be and new mums; Dr Shubhangi talked about the importance of stem cells and newborn screening; Manoj Mehta from ISP - The Art of Parenting programme introduced the concept of holistic parenting; and childbirth educator Seema Kazi explained the do's and don'ts for expectant mums. Bellydance moves that help to strengthen the pelvic and deep abdominal muscles, which are used while giving birth, were taught to enthusiastic mums-to-be by Veronica Simas de Souza, director of the Veve Dance Institute.

MOMENTS TO CHERISH!



Bengaluru's MLR Convention Centre also saw mums-to-be and mums enjoying a fabulous day out on September 22. My Beautiful Bump, a fashion show, beauty pageant and panel discussion all rolled into one was organised by Cherishmaternity.com in partnership with Dr Malathi Manipal Hospitals and Mother & Baby and Columbia Asia Hospitals, Manipal Hospitals, Taxiforsure, Babycell, Fever104, Deccan Herald, Narayana Health city, Kosmos skin care, Body craft, Pizza corner and TNexpress as supporting partners. The panel discussion conducted by Vasanthi Hariprakash included Dr Jyotsna Madan, Dr Bharathi Rajanna, Dr Gayatri Karthik and Anindita Sengupta and revolved around subjects such as natural birth, breastfeeding, etc, followed by an ind-depth Q&A session. A beauty pageant featuring yummy mummies was judged

BusinessLine

Apollo Hospitals ties up with cell therapy firm

Pratap C Reddy, Chairman, Apollo Hospitals, with Satyen Sanghavi (left), Chief Scientific Officer, RMS Regrow, and Yash Sanghavi, CEO, in New Delhi on Monday - Photo: KAMAL NARANG

Partnership will help hospital chain offer innovative orthopaedic treatment

NEW DELHI, JUNE 19: Patients suffering from orthopaedic problems such as arthritis may now have a better and painless option than replacement surgeries.

The country's largest hospital chain, Apollo Hospitals, on Monday entered into a tie-up with a Pune-based up-and-coming regenerative medicine company RMS Regrow to offer cell therapy treatment for bone and cartilage problems.

This exclusive partnership with RMS Regrow will allow the Chennai-headquartered hospital chain to offer advanced cell therapy treatment to patients suffering from a variety of bone or cartilage related problems caused by sports injury, accidents, ageing or wear and tear. In India, more than 1.5 million orthopaedic procedures are performed every year.

PHARMABIZ.com

India's most comprehensive pharma portal

Apollo & RMS REGROW bring to India first of its kind innovative cell therapy treatment for orthopedic patients

Our Bureau, Mumbai
Monday, June 19, 2017, 16:30 Hrs [IST]

Apollo Hospitals, Asia's largest and most trusted healthcare group, has partnered with RMS REGROW, the first 'Make in India' Company in Cell Therapy Technology, to offer two new Regenerative Medicine Cell Therapy products- Ossron and Chondron for bone and cartilage problems, respectively. The two products will address unmet clinical needs in the orthopaedic market with respect to sports injuries, accidents and alternate to hip replacements and knee replacements for a young arthritic knee. In an exclusive tie up between Apollo Hospitals and RMS Regrow, the treatment therapy will be made available across all Apollo Hospitals, Apollo Spectra Hospitals and Apollo clinics in India.

Ossron and Chondron are the results of a dedicated research team at REGROW. The two products are innovative proprietary and patented technology which has been developed for both the products following the regulatory guidelines. Through several clinical trials and evaluation studies over 8 years, the company has achieved the market authorization for the two cell therapy products.

As an exclusive offering, Apollo Hospitals will create a platform for orthopaedic doctors to practice Regenerative Medicine efficiently by conducting live surgical workshops, CME's for doctors and conferences (national and international).

Speaking on the occasion, Dr Prathap C Reddy, Founder-Chairman of Apollo Hospitals, said: "Bringing innovation in healthcare and addressing the unmet medical needs of India has been the foremost aim of the Apollo Group. In our quest to do so, we also want to encourage research and innovation within India for the people of India. Our association with RMS Regrow is a step to inspire talent in India to further the advancement in developing innovative healthcare treatments to reduce the growing disease burden in India."

Commenting on the launch Yash Sanghavi, founder and chief executive officer of RMS REGROW: "We are delighted to partner with a leader like Apollo Hospitals which offers RMS REGROW unprecedented opportunity to reach patients pan India. It has taken 8 years of dedicated effort and innovative research to develop the two revolutionary products that will change the modalities for bone and cartilage treatment in India. Since last 70 years, only a handful of New Chemical Entities (NCE) have been developed in India, which demonstrates a dearth of innovator drugs and new medical technologies to address a large market of bone and joint disorders. In India, more than 15 lac (~15, 00,000) orthopaedic procedures are performed each year and Regenerative Cell Therapy is a revolutionary treatment methodology which has immense potential to liberate consumers from Joint pain."

Also present on the occasion was Ms Sangita Reddy, Joint Managing Director, Apollo Hospitals. Commenting on the development, she says "At Apollo Hospitals, bringing innovative treatments to improve the quality of life of our patients is paramount. We have also developed the expertise to create ecosystems that enable use of the developing health technology. These two products are revolutionary and Apollo's doctors in partnership with RMS REGROW, will develop workshops and educative sessions across India to bring this technology to practice at the earliest."

hindustantimes

Apollo Hospitals bring innovative cell therapy to treat joint pain

Apollo Hospitals and RMS REGROW will bring to India first of its kind innovative cell therapy for orthopaedic patients.

Dr Prathap C Reddy, founder-chairman, Apollo Hospitals (2nd from left) announcing the partnership to bring innovative cell therapy to India (HT photo)

Making uses of the advances in cell therapy, Apollo Hospitals on Tuesday announced partnership with RMS REGROW, to offer new regenerative medicine cell therapy products that will be a boon for patients suffering from bone and cartilage damage.

The two products- Ossron and Chondron, will address unmet clinical needs in the orthopaedic market with respect to sports injuries, accidents and alternate to hip replacements and knee replacements for a young arthritic knee.

In an exclusive tie up between Apollo Hospitals and RMS Regrow, the treatment therapy will be made available across all Apollo Hospitals, Apollo Spectra Hospitals and Apollo clinics in India.

babycell®

Preserve Your Love

A UNIT OF RMS

RECOGNIZED AS RESEARCH & DEVELOPMENT UNIT

by the Department of Science and Industrial Research (DSIR)
Ministry of Science and Technology, Govt of India

FDA ISO 13485 GMP GCP GLP

REGENERATIVE MEDICAL SERVICES PVT. LTD.

Head Office: 2-ABC, Acme Plaza, Andheri East, Mumbai - 400059, India.
Tel.: +91 22 6733 0300 | E-mail: info@babycell.in | Website: www.babycell.in
CIN: U24100MH1989PTC054162 | GST No. 27AADCS4917N1ZW

Toll Free No.: 1800-209-0309 SMS 'Babycell' to 56677

SOP/PR/BC/006 Annex. I (Version No. 04)